Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines☆
Affiliations
- Olive View–UCLA Medical Center, North Annex, Sylmar, CA 91342
Correspondence
- Corresponding author. Tel.: +1 818 3643110; fax: +1 818 3643268.

Affiliations
- Olive View–UCLA Medical Center, North Annex, Sylmar, CA 91342
Correspondence
- Corresponding author. Tel.: +1 818 3643110; fax: +1 818 3643268.

Affiliations
- The Johns Hopkins University School of Medicine, Baltimore, MD
Affiliations
- University of Massachusetts Medical School, Worcester, MA
Article Info
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.
Fig. 1
Prevalence of pathogens among those with an identified pathogen in adults hospitalized with CAP from 12 university-affiliated EDs. MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S aureus.
Fig. 2
Flowchart for use of SMART-COP (reproduced from Charles et al [67] , with permission).
Abstract
Community-acquired pneumonia (CAP) is a major health problem in the United States and is associated with substantial morbidity, mortality, and health care costs. Patients with CAP commonly present to emergency departments where physicians must make critical decisions regarding diagnosis and management of pneumonia in a timely fashion, with emphasis on efficient and cost-effective diagnostic choices, consideration of emerging antimicrobial resistance, timely initiation of antibiotics, and appropriate site-of-care decisions. In light of the burden that pneumonia places on health care systems and the emergency department in particular, this article reviews significant developments in the management of CAP in the United States 5 years since the publication of the 2007 Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of CAP in adults, focusing on recent studies and recommendations for managing CAP, the primary bacterial pathogens responsible for CAP, and trends in resistance, new diagnostic technologies, and newer antimicrobials approved for the treatment of CAP. These new data and additional guidelines pertaining to the treatment of CAP further our knowledge and understanding of this challenging infection. Furthermore, appreciation of the availability of new diagnostic testing and therapeutic options will help meet the demand for improved management of CAP.
To access this article, please choose from the options below
Purchase access to this article
Claim Access
If you are a current subscriber with Society Membership or an Account Number, claim your access now.
Subscribe to this title
Purchase a subscription to gain access to this and all other articles in this journal.
Institutional Access
Visit ScienceDirect to see if you have access via your institution.
☆This work was financially supported by Forest Research Institute, Inc.
Related Articles
Searching for related articles..
